Strongyloides-An uncommon cause of eosinophilia whilst on durvalumab.

Gaik Tin Quah, Gillian Blanchard, Neil Miller, Paul Wilson, Ina Nordman

Open access · goldAbstract readCase Reports

In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

0.2field-weighted citation impact, top 48% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

Strongyloides-An uncommon cause of eosinophilia whilst on durvalumab.Cancer reports (Hoboken, N.J.) · 2022
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Gaik Tin QuahDepartment of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.ORCID 0000-0002-9177-7442

Gillian BlanchardDepartment of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.

Neil MillerDepartment of Infectious Diseases, Calvary Mater Newcastle, Waratah, Australia.

Paul WilsonDepartment of Infectious Diseases, Calvary Mater Newcastle, Waratah, Australia.

Ina NordmanDepartment of Medical Oncology, Calvary Mater Newcastle, Waratah, Australia.

Calvary Mater Newcastle Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn malignancy, eosinophils have been shown to play an important role in the tumour micro-environment. Increasingly, development of eosinophilia with immune checkpoint inhibitor (ICI) use is thought to be predictive of prognosis and development of immune-related adverse events. However, there are many other causes for developing eosinophilia which can contribute to the difficulties in diagnosis and management. CASE: Here, we present a case of Strongyloides parasitic infection as an uncommon differential for eosinophilia in a patient with lung cancer receiving a PDL-1 ICI, durvalumab, in Australia.

conclusionThis case highlights the complexities exploring the multiple potential causes of eosinophilia and the subsequent management, to allow safe continuation of ICI.

Indexed as

EosinophiliaStrongyloidiasisAnimalsAntibodies, MonoclonalHumansImmune Checkpoint InhibitorsStrongyloidesAntibodies, MonoclonaldurvalumabImmune Checkpoint Inhibitorsdurvalumabeosinophiliaimmune checkpoint inhibitorsimmunotherapyStrongyloides

Identifiers

PMID35852050

DOI10.1002/cnr2.1682

PMCPMC9575490

OpenAlexW4285803312

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.